We are live on ! Find out more
AUPH icon

Aurinia Pharmaceuticals
AUPH

64 hedge funds and large institutions have $113M invested in Aurinia Pharmaceuticals in 2018 Q1 according to their latest regulatory filings, with 10 funds opening new positions, 19 increasing their positions, 17 reducing their positions, and 14 closing their positions.

New
Increased
Maintained
Reduced
Closed

12% more repeat investments, than reductions

Existing positions increased: 19 | Existing positions reduced: 17

4% more capital invested

Capital invested by funds: $108M → $113M (+$4.76M)

2.54% less ownership

Funds ownership: 28.38% → 25.84% (-2.5%)

6% less funds holding

Funds holding: 68 → 64 (-4)

29% less first-time investments, than exits

New positions opened: 10 | Existing positions closed: 14

79% less call options, than puts

Call options by funds: $595K | Put options by funds: $2.79M

Holders
64
Holders Change
-4
Holders Change %
-5.88%
% of All Funds
1.47%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
10
Increased
19
Reduced
17
Closed
14
Calls
$595K
Puts
$2.79M
Net Calls
-$2.2M
Net Calls Change
-$73K

Top Buyers

Rank Fund Capital Flow
1
BlackRock
BlackRock
New York
+$1.74M
2
Morgan Stanley
Morgan Stanley
New York
+$1.28M
3
D.E. Shaw & Co
D.E. Shaw & Co
New York
+$1.24M
4
PC
Polar Capital
United Kingdom
+$1.07M
5
Goldman Sachs
Goldman Sachs
New York
+$254K

Top Sellers

Rank Fund Capital Flow
1
O
OrbiMed
New York
-$6.27M
2
Point72 Asset Management
Point72 Asset Management
Connecticut
-$2.43M
3
Balyasny Asset Management
Balyasny Asset Management
Illinois
-$2.27M
4
AIC
AWM Investment Company
New York
-$1.61M
5
Fidelity Investments
Fidelity Investments
Massachusetts
-$1.13M
Name Holding Trade Value Shares
Change 		Change in
Stake
ProShare Advisors
26
ProShare Advisors
Maryland
$202K +$53.9K +10,078 +35%
Two Sigma Advisers
27
Two Sigma Advisers
New York
$197K -$56.2K -10,500 -22%
Deutsche Bank
28
Deutsche Bank
Germany
$196K +$152K +28,401 +300%
Man Group
29
Man Group
United Kingdom
$170K +$175K +32,800 New
DS
30
DRW Securities
Illinois
$162K +$167K +31,300 New
RJFSA
31
Raymond James Financial Services Advisors
Florida
$149K +$12K +2,250 +8%
CS
32
Credit Suisse
Switzerland
$147K +$48.3K +9,021 +47%
Geode Capital Management
33
Geode Capital Management
Massachusetts
$129K – – –
Wells Fargo
34
Wells Fargo
California
$126K +$24.7K +4,622 +24%
SOMRS
35
State of Michigan Retirement System
Michigan
$117K – – –
ICA
36
Infrastructure Capital Advisors
New York
$114K +$14.4K +2,700 +14%
Stifel Financial
37
Stifel Financial
Missouri
$113K +$57.6K +10,772 +98%
Simplex Trading
38
Simplex Trading
Illinois
$86K +$72.4K +13,533 +440%
BCM
39
Bayesian Capital Management
New York
$85K +$87.2K +16,300 New
Royal Bank of Canada
40
Royal Bank of Canada
Ontario, Canada
$84K -$5.02K -939 -5%
Vanguard Group
41
Vanguard Group
Pennsylvania
$77K – – –
PFGIA
42
Patriot Financial Group Insurance Agency
Massachusetts
$62K +$5.89K +1,100 +10%
MOS
43
MGO One Seven
Ohio
$57K – – –
LCS
44
Levin Capital Strategies
New York
$52K – – –
Canada Life
45
Canada Life
Manitoba, Canada
$35K – – –
BBHC
46
Brown Brothers Harriman & Co
New York
$34K – – –
FDCDDQ
47
Federation des caisses Desjardins du Quebec
Quebec, Canada
$27.3K +$7.33K +1,370 +35%
SAM
48
Shell Asset Management
Netherlands
$27K +$5.89K +1,100 +27%
Citigroup
49
Citigroup
New York
$18K -$7.86K -1,469 -30%
TRCT
50
Tower Research Capital (TRC)
New York
$18K -$5.81K -1,086 -25%
1
2
3 4

AUPH Hedge Fund Activity: Q1 2018 in Review

64 of the 4,363 institutional investors tracked by Wall St. Rank reported a position in Aurinia Pharmaceuticals (AUPH) for Q1 2018, worth a combined $113M — up 4.4% from $108M a quarter earlier.

Sellers outnumbered buyers: 14 funds closed out of AUPH and 10 opened new positions — a net loss of 4 holders — while 17 trimmed existing stakes and 19 added.

The largest buyer was BlackRock, adding an estimated $1.74M. The largest seller was OrbiMed, cutting an estimated $6.27M.

  • 64 institutional investors held Aurinia Pharmaceuticals (AUPH) as of Q1 2018, down from 68 in Q4 2017.
  • Funds reported $113M of Aurinia Pharmaceuticals stock for Q1 2018, up 4.4% quarter-over-quarter.
  • 10 funds opened new Aurinia Pharmaceuticals positions in Q1 2018 and 14 closed out, a net change of -4 holders.
  • The largest Aurinia Pharmaceuticals buyer in Q1 2018 was BlackRock, an estimated $1.74M added.
  • The largest Aurinia Pharmaceuticals seller in Q1 2018 was OrbiMed, an estimated $6.27M sold.

Based on aggregated 13F filings for Q1 2018.